Companion Animal Pharmaceuticals Market Size & Share Analysis - Growth, Trends, And Forecasts (2025 - 2030)

The Companion Animal Pharmaceuticals Market Report is Segmented by Indication (Infectious Diseases, Dermatologic Diseases, Orthopedic Diseases, Ophthalmic Diseases, and Other Indications), Animal Type (Dogs, Cats, and Other Companion Animals), Distribution Channel (Veterinary Hospitals and Clinics, and Retail Pharmacies), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The Report Offers the Value (USD) for the Above Segments.

Companion Animal Pharmaceuticals Market Size & Share Analysis - Growth, Trends, And Forecasts (2025 - 2030)

Companion Animal Pharmaceuticals Market Size

Companion Animal Pharmaceuticals Market Summary
Study Period 2019 - 2030
Market Size (2025) USD 18.16 Billion
Market Size (2030) USD 26.81 Billion
CAGR (2025 - 2030) 8.10 %
Fastest Growing Market Asia-Pacific
Largest Market North America
Market Concentration Medium

Major Players

Companion Animal Pharmaceuticals Market Major Players

*Disclaimer: Major Players sorted in no particular order

Compare market size and growth of Companion Animal Pharmaceuticals Market with other markets in Healthcare Industry

Biotechnology

Pharmaceuticals

Healthcare IT

Medical Devices

Animal Health

Device Drug Combination

Companion Animal Pharmaceuticals Market Analysis

The Companion Animal Pharmaceuticals Market size is estimated at USD 18.16 billion in 2025, and is expected to reach USD 26.81 billion by 2030, at a CAGR of 8.1% during the forecast period (2025-2030).

The rising adoption of companion animals is set to boost the use of animal pharmaceuticals, particularly for treating infectious and orthopedic diseases, thereby propelling market growth during the forecast period. For instance, the 2023-2024 National Pet Owners Survey by the American Pet Products Association (APPA) revealed that approximately 66% of U.S. households, translating to 86.9 million homes, owned pets. This includes 46.5 million cats and 65.1 million dogs, with cats and dogs being the most commonly adopted animals globally.

Furthermore, the surging demand for pet insurance, coupled with rising expenditures on animal health, is anticipated to further drive the use of pharmaceuticals for treating companion animals. For instance, data from January 2024 by the North American Pet Health Insurance Association highlighted a 17.1% increase in insured pets in the U.S. compared to 2023. In the U.S., dogs dominate the insurance landscape, making up 78.6% of insured pets, while cats represent 21.4%. This growing insurance demand is set to further fuel the market for animal medicines.

In Europe, pet ownership is equally prevalent. In the United Kingdom, a 2023 survey by the Pet Food Manufacturers' Association (PFMA) indicated that 62% of households owned pets, with around 13.5 million dogs, representing 36% of all households.

Pets are susceptible to various internal and external parasites, which can pose health risks to both the animals and their owners. An April 2024 study by MDPI highlighted that over 62.6% of dogs in Serbia are affected by endoparasites. These include intestinal parasites like Cystoisospora spp. (9.2%), Giardia intestinalis (11.8%), and Toxocara canis (11.5%). Given the global popularity of dogs as pets, there's a potential for these infections to transfer to humans. This scenario underscores the critical need for effective parasite control and the growing demand for companion animal pharmaceuticals, which are essential in managing and preventing such infections, safeguarding both pet and public health.

In summary, the increasing adoption of companion animals, the rising demand for pet insurance, and heightened expenditures on animal health are poised to drive market growth in the coming years.

Companion Animal Pharmaceuticals Industry Overview

The companion animal pharmaceuticals market is fragmented and consists of several major players. A few major players are currently dominating the market, including Zoetis Inc., Merck & Co. Inc., Boehringer Ingelheim GmbH, Elanco Animal Health Incorporated, Virbac, Ceva Santé Animale, and Dechra Pharmaceuticals PLC.

Companion Animal Pharmaceuticals Market Leaders

  1. Boehringer Ingelheim International GmbH

  2. Ceva Santé Animale

  3. Chanelle Pharma

  4. Dechra

  5. Elanco

  6. *Disclaimer: Major Players sorted in no particular order
Companion Animal Pharmaceuticals Market Concentratiion
Need More Details on Market Players and Competiters?
Download PDF

Companion Animal Pharmaceuticals Market News

  • April 2024: Following approval from the Central Drugs Standard Control Organization (CDSCO), Boehringer Ingelheim announced the launch of NexGard SPECTRA (afoxolaner and milbemycin oxime) in India. NexGard SPECTRA, a palatable chewable for dogs, provides comprehensive control against both internal and external parasites with just one monthly dose.
  • January 2024: Ceva Santé Animale, a prominent player in the animal health sector, has strategically acquired Scout Bio, a biotech firm renowned for its pioneering therapies for pets. This acquisition marks a pivotal stride in Ceva's innovation journey, granting them access to significant advancements. These include a robust pipeline of monoclonal antibodies and groundbreaking gene therapy developments, both aimed at tackling chronic diseases in pets.

Companion Animal Pharmaceuticals Market Report - Table of Contents

1. INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Adoption of Companion Animals
    • 4.2.2 Growing Demand for Pet Insurance Coupled with Increasing Animal Health Expenditure
  • 4.3 Market Restraints
    • 4.3.1 Stringent Regulation for Animal Vaccines
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5. MARKET SEGMENTATION (Market Size Value in USD)

  • 5.1 Indication
    • 5.1.1 Infectious Diseases
    • 5.1.2 Dermatologic Diseases
    • 5.1.3 Orthopedic Diseases
    • 5.1.4 Ophthalmic Diseases
    • 5.1.5 Other Indications
  • 5.2 Animal Type
    • 5.2.1 Dogs
    • 5.2.2 Cats
    • 5.2.3 Other Companion Animals
  • 5.3 Distribution Channel
    • 5.3.1 Veterinary Hospitals and Clinics
    • 5.3.2 Retail Pharmacies
  • 5.4 Geography
    • 5.4.1 North America
    • 5.4.1.1 United States
    • 5.4.1.2 Canada
    • 5.4.1.3 Mexico
    • 5.4.2 Europe
    • 5.4.2.1 Germany
    • 5.4.2.2 United Kingdom
    • 5.4.2.3 France
    • 5.4.2.4 Italy
    • 5.4.2.5 Spain
    • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
    • 5.4.3.1 China
    • 5.4.3.2 Japan
    • 5.4.3.3 India
    • 5.4.3.4 Australia
    • 5.4.3.5 South Korea
    • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle East and Africa
    • 5.4.4.1 GCC
    • 5.4.4.2 South Africa
    • 5.4.4.3 Rest of Middle East and Africa
    • 5.4.5 South America
    • 5.4.5.1 Brazil
    • 5.4.5.2 Argentina
    • 5.4.5.3 Rest of South America

6. COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Boehringer Ingelheim International GmbH
    • 6.1.2 Ceva Sante Animale
    • 6.1.3 Chanelle Pharma
    • 6.1.4 Dechra
    • 6.1.5 Elanco
    • 6.1.6 HIPRA
    • 6.1.7 Merck & Co. Inc.
    • 6.1.8 Vetoquinol SA
    • 6.1.9 Virbac
    • 6.1.10 Zoetis, Inc.
  • *List Not Exhaustive

7. MARKET OPPORTUNITIES AND FUTURE TRENDS

You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Companion Animal Pharmaceuticals Industry Segmentation

Companion animal pharmaceuticals are used to treat, sedate, and improve the health and performance of the pet or companion animal. 

The companion animal pharmaceuticals market is segmented by indication, animal type, distribution channel, and geography. By indication, the market is segmented into infectious diseases, dermatologic diseases, orthopedic diseases, ophthalmic diseases, and other indications. By animal type, the market is segmented into dogs, cats, and other companion animals. By distribution channel, the market is segmented into veterinary hospitals and clinics and retail pharmacies. By geography, the market is segmented into North America, Europe, Asia-Pacific, Middle East and Africa, and South America. The report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (USD) for all the above segments.

Indication Infectious Diseases
Dermatologic Diseases
Orthopedic Diseases
Ophthalmic Diseases
Other Indications
Animal Type Dogs
Cats
Other Companion Animals
Distribution Channel Veterinary Hospitals and Clinics
Retail Pharmacies
Geography North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
South America Brazil
Argentina
Rest of South America
Need A Different Region or Segment?
Customize Now

Companion Animal Pharmaceuticals Market Research FAQs

How big is the Companion Animal Pharmaceuticals Market?

The Companion Animal Pharmaceuticals Market size is expected to reach USD 18.16 billion in 2025 and grow at a CAGR of 8.10% to reach USD 26.81 billion by 2030.

What is the current Companion Animal Pharmaceuticals Market size?

In 2025, the Companion Animal Pharmaceuticals Market size is expected to reach USD 18.16 billion.

Who are the key players in Companion Animal Pharmaceuticals Market?

Boehringer Ingelheim International GmbH, Ceva Santé Animale, Chanelle Pharma, Dechra and Elanco are the major companies operating in the Companion Animal Pharmaceuticals Market.

Which is the fastest growing region in Companion Animal Pharmaceuticals Market?

Asia-Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).

Which region has the biggest share in Companion Animal Pharmaceuticals Market?

In 2025, the North America accounts for the largest market share in Companion Animal Pharmaceuticals Market.

What years does this Companion Animal Pharmaceuticals Market cover, and what was the market size in 2024?

In 2024, the Companion Animal Pharmaceuticals Market size was estimated at USD 16.69 billion. The report covers the Companion Animal Pharmaceuticals Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Companion Animal Pharmaceuticals Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.

Companion Animal Pharmaceuticals Industry Report

Statistics for the 2025 Companion Animal Pharmaceuticals market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Companion Animal Pharmaceuticals analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.